Therapeutic Asset Ratings

3,227 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Sufentanyl Liver Cancer	The Second Affiliated Hospital of Chongqing Medical University	P4	B (60)
Sufentanyl Inflammatory Disease	The First Affiliated Hospital with Nanjing Medical University	P4	B (60)
Suvorexant Delirium	Mayo Clinic	P4	B (60)
Talquetamab Waldenstrom Macroglobulinemia	Anne Louise Tølbøll Sørensen	P4	B (60)
Tavor Bipolar Disorder	Dr. Stavroula Rakitzi	P4	B (60)
Tazobactam Bronchiectasis	Sunshine Coast Hospital and Health Service	P4	B (60)
Teclistamab Waldenstrom Macroglobulinemia	Anne Louise Tølbøll Sørensen	P4	B (60)
Telmisartan Essential Hypertension	Yuhan Corporation	P4	B (60)
Tenofovir Alafenamide Fatty Liver Disease	Fundacion SEIMC-GESIDA	P4	B (60)
Tenofovir Disoproxil Fumarate Hepatocellular Carcinoma	Ningbo No.2 Hospital	P4	B (60)
Thalidomide Non-Small Cell Lung Carcinoma	Henan Cancer Hospital	P4	B (60)
Tirzepatide Atherosclerotic Cardiovascular Disease	Brigham and Women's Hospital	P4	B (60)
Tirzepatide Acquired Hypothalamic Obesity	Grace Kim	P4	B (60)
Tirzepatide Osteoporosis	Pennington Biomedical Research Center	P4	B (60)
Tirzepatide Polycystic Ovary Syndrome	University of Bonn	P4	B (60)
Tirzepatide Prader-Willi Syndrome	Grace Kim	P4	B (60)
Topiramate Tinnitus	Stanford University	P4	B (60)
Trametinib Astrocytic Tumor	Novartis Pharmaceuticals	P4	B (60)
Trametinib Neoplasm	Cancer Research UK	P4	B (60)
Tranexamic Acid Cirrhosis Of Liver	Tanta University	P4	B (60)
Tranexamic Acid Malignant Colon Neoplasm	Assaf-Harofeh Medical Center	P4	B (60)
Trazodone Major Depressive Disorder	Centre Hospitalier St Anne	P4	B (60)
Ubrogepant Migraine Without Aura	Messoud Ashina, MD	P4	B (60)
Umbellatine Helicobacter Pylori Infectious Disease	Nanjing First Hospital, Nanjing Medical University	P4	B (60)
Umbellatine Prediabetes Syndrome	Yu Chen	P4	B (60)

Showing 2526 to 2550 of 3,227 assets

PreviousPage 102 of 130Next